Abstract Library

#3257 Molecular and functional study of somatostatin receptors in pheochromocytomas and paragangliomas

Introduction: Most pheochromocytomas (PCC) and paragangliomas (PGL) are benign neuroendocrine tumors that overproduce catecholamines causing hypertension, arrhythmia, and stroke; however, 10 30% may present distant metastasis. About 40% are caused by germline mutations, which may be classified in 3 different clusters. PCC/PGL diagnosis involves blood/urine tests and imaging techniques, while their treatment often requires distinct pharmacological and surgical approaches. Thus, identification of new biomarkers for early diagnosis, and progression/response would help to avoid unnecessary tests and enable personalized medicine approaches.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ibáñez-Costa A

Authors: Ibáñez-Costa A, Blázquez-Encinas R, Alors-Pérez E, Fuentes-Fayos A, Rivero-Cortés E,

Keywords: pheochromocytoma, paraganglioma, somatostatin, somatostatin receptor, neuroendocrine tumor,

#2116 Ghrelin O-Acyltransferase (GOAT) Enzyme and Ghrelin Receptor GHSR1a as Putative Prognosis Markers and Therapeutic Targets in Gastroenteropancreatic Neuroendocrine Tumors

Introduction: Specific components of ghrelin-system are associated with tumor development/ progression. We have previously described the presence of this system in neuroendocrine tumors (NETs) but clinical-molecular correlations have not been elucidated yet.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Herrera-Martinez A

Authors: Herrera-Martínez A, Gahete M, Sánchez-Sánchez R, Ortega Salas R, Serrano R,

Keywords: GEP-NET, ghrelin system, GOAT, GHSR1a, prognosis, invasion,

#1494 CDK-Inhibitors as New Therapeutic Treatment for Human Bronchial Carcinoids

Introduction: Bronchial Carcinoids (BC) are still orphan of medical therapy. We previously demonstrated that 70% of primary BC cultures are sensitive to Everolimus (E), an mTOR inhibitor, while 30% are not. We also observed that in 2 human BC cell lines, the NCI-H720 (sensitive to E) and NCI-H727 (resistant to E), mTOR resistance may be linked to a differential cell cycle protein expression (CyclinD1/E, CDK2/4, p27kip1/p27kip1phospho-Ser10), which is higher in BC resistant to E as compared to sensitive ones, suggesting an impaired p27 function

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: BENFINI K

Authors: Benfini K, Gentilin E, Riva E, Di Pasquale C, Falletta S,

Keywords: Bronchial Carcinoid, Medical Therapy, mTOR Resistance, CDK inhibitors,

#1476 Efficacy of Everolimus and Somatostatin Analogs as Single Agents or in Combination in Human Pancreatic Neuroendocrine Tumors Primary Cultures

Introduction: Among the therapeutic options available for the treatment of neuroendocrine tumors, one targeted therapy, everolimus (RAD) has been approved for advanced progressive pancreatic neuroendocrine tumors (pNETs). It improve progression free survival but is not curative. Alterations of the PI3K/Akt/mTOR pathway in pNETs have given the rational for the use of this signaling pathway inhibitors.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Romano D

Authors: Mohamed A, Romano D, Poizat F, Delpero J, Niccoli P,

Keywords: pNETs primary culture, everolimus, somatostatin analogues, cell viability, chromogranin A secretion, Akt activity,

#1173 Investigation of the Effects of Sunitinib on Pheochromocytoma and Paraganglioma Primary Cultures

Introduction: The main treatment for Pheochromocytoma and Paraganglioma is surgery. However these tumors are highly vascularized, suggesting the possible role for anti-angiogenic agents in the medical therapy. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor (TKI), mainly described to inhibit VEGFR

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Bellio M, Gagliano T, Feo C, Balboni F, Gentilin E,

Keywords: Sunitinib, Pheochromocytoma, Paraganglioma ,